{"gene":"TRAPPC11","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2013,"finding":"TRAPPC11 is a component of the multiprotein TRAPP complex; disease-causing mutations (p.Gly980Arg and p.Ala372_Ser429del) impair binding of TRAPPC11 to other TRAPP complex components and disrupt Golgi apparatus architecture. The p.Ala372_Ser429del deletion causes normal ER-to-Golgi trafficking but dramatically delayed exit from the Golgi to the cell surface, and results in alterations of lysosomal membrane glycoproteins LAMP1 and LAMP2.","method":"Co-immunoprecipitation to assess TRAPP complex binding; marker trafficking experiments in patient fibroblasts; immunofluorescence of Golgi and lysosomal markers","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, trafficking marker experiments, and Golgi morphology analysis with two distinct patient mutations; replicated in subsequent studies","pmids":["23830518"],"is_preprint":false},{"year":2016,"finding":"TRAPPC11 is required for lipid-linked oligosaccharide (LLO) biosynthesis and protein glycosylation; loss of trappc11 in zebrafish reduces LLO levels and triggers compensatory up-regulation of the terpenoid biosynthetic pathway (dolichol production). Depletion of TRAPPC11 (but not other TRAPP components) in human cells causes protein hypoglycosylation, and lipid droplets accumulate in patient fibroblasts. Inhibition of terpenoid or LLO synthesis phenocopies the stressed unfolded protein response (UPR) seen in trappc11 mutants.","method":"Zebrafish genetic mutant analysis; LLO quantification; qRT-PCR of terpenoid pathway genes; pharmacological inhibitors phenocopy; siRNA knockdown of individual TRAPP components in human cells; patient fibroblast analysis","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (genetic mutant, biochemical LLO assay, pharmacological phenocopy, human cell depletion), conserved across zebrafish and human cells","pmids":["26912795"],"is_preprint":false},{"year":2016,"finding":"A TRAPPC11 splice mutation (c.1893+3A>G) causes incomplete exon skipping, reduction in full-length TRAPPC11 protein, hypoglycosylation of LAMP1, and delays in both arrival of cargo at the Golgi and release from the Golgi to the plasma membrane in patient fibroblasts.","method":"Western blot; trafficking marker experiments in patient fibroblasts; immunofluorescence for LAMP1 glycosylation","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — trafficking assays and glycosylation readout in patient fibroblasts, single lab, two orthogonal methods","pmids":["27707803"],"is_preprint":false},{"year":2018,"finding":"TRAPPC11 mutations are associated with hypoglycosylation of α-dystroglycan; compound heterozygous TRAPPC11 mutations in a patient confirm abnormal membrane trafficking in fibroblasts, establishing a link between a membrane trafficking protein and the dystroglycanopathy group of muscular dystrophies.","method":"Immunofluorescence and western blotting for α-dystroglycan glycosylation in muscle biopsy; live cell trafficking analysis in patient fibroblasts","journal":"Skeletal muscle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunofluorescence, western blot, and live cell trafficking assays in patient material, single lab","pmids":["29855340"],"is_preprint":false},{"year":2019,"finding":"The carboxy-terminal region of TRAPPC11 is critical for its functions: a frameshift extending the C-terminus (p.Asp1127Valfs*47) combined with a foie gras domain deletion causes defects in ER-to-Golgi transport, delayed Golgi exit, glycosylation defects of an ER-resident glycoprotein, and autophagic flux defects. Subjects with only the Gly980Arg missense variant showed trafficking and glycosylation defects but not autophagic flux defects, indicating domain-specific functional contributions.","method":"Trafficking marker assays in patient fibroblasts; glycosylation assays; autophagic flux assays (LC3-II accumulation with/without bafilomycin)","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple patient variants with orthogonal functional assays (trafficking, glycosylation, autophagy), single lab","pmids":["31575891"],"is_preprint":false},{"year":2021,"finding":"TRAPPC11 is important for TRAPP complex integrity and anterograde membrane transport from the ER to the ER-Golgi intermediate compartment; recessive mutations cause hypoglycosylation of α-dystroglycan in both skeletal muscle and brain (including Purkinje cells and dentate neurons), with neuropathology resembling N-linked congenital disorders of glycosylation.","method":"Membrane trafficking assays; immunofluorescence with IIH6 antibody for α-dystroglycan glycosylation in muscle biopsy and post-mortem brain; western blot","journal":"Neuropathology and applied neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — trafficking assays and glycosylation immunofluorescence in patient tissue, single lab, multiple orthogonal methods","pmids":["34648194"],"is_preprint":false},{"year":2023,"finding":"TRAPPC11 deficiency is associated with decreased mitochondrial ATP production capacity and alterations in mitochondrial network architecture, expanding TRAPPC11's functional role beyond membrane trafficking and glycosylation.","method":"Mitochondrial function assays (ATP production) and mitochondrial network imaging in patient-derived cells","journal":"Journal of medical genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional assays in patient cells but single lab, single study, limited mechanistic follow-up","pmids":["37197784"],"is_preprint":false},{"year":2024,"finding":"Membrane trafficking assays in fibroblasts from a TRAPPC11 compound heterozygous patient show defective ER-to-Golgi transport and decreased expression of glycoproteins LAMP2 and ICAM-1, consistent with TRAPPC11-opathy being a congenital disorder of glycosylation (CDG).","method":"Membrane trafficking assays; western blot/immunofluorescence for LAMP2 and ICAM-1 in patient fibroblasts","journal":"Molecular genetics and metabolism","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single patient fibroblast study, single lab, replicates prior findings without new mechanistic depth","pmids":["38564972"],"is_preprint":false}],"current_model":"TRAPPC11 is a subunit of the TRAPP III complex that mediates anterograde membrane trafficking from the ER through the Golgi to the cell surface; it is uniquely required (among TRAPP subunits) for lipid-linked oligosaccharide (LLO) biosynthesis and protein N-glycosylation (including glycosylation of α-dystroglycan, LAMP1/2, and ICAM-1), and its loss activates a pathological unfolded protein response, disrupts autophagic flux, and impairs mitochondrial function, with disease-causing mutations in its foie gras or gryzun domains impairing binding to other TRAPP components and disrupting Golgi architecture."},"narrative":{"mechanistic_narrative":"TRAPPC11 is a subunit of the multiprotein TRAPP complex that mediates anterograde membrane trafficking, with a particular requirement for cargo exit from the Golgi to the cell surface [PMID:23830518]. Disease-causing mutations in its C-terminal domains, including the foie gras and gryzun regions, impair TRAPPC11 binding to other TRAPP components and disrupt Golgi architecture, producing a dual defect in ER-to-Golgi transport and delayed Golgi-to-plasma-membrane exit [PMID:23830518, PMID:31575891]. Beyond bulk trafficking, TRAPPC11 is uniquely required among TRAPP subunits for lipid-linked oligosaccharide (LLO) biosynthesis and protein N-glycosylation: its loss reduces LLO levels, drives compensatory up-regulation of the terpenoid (dolichol) pathway, and causes protein hypoglycosylation that phenocopies a stressed unfolded protein response [PMID:26912795]. This glycosylation deficit affects specific substrates including the lysosomal membrane glycoproteins LAMP1/LAMP2, ICAM-1, and α-dystroglycan, the last linking TRAPPC11 loss to the dystroglycanopathy spectrum and to N-linked congenital disorders of glycosylation affecting muscle and brain [PMID:23830518, PMID:29855340, PMID:34648194, PMID:38564972]. TRAPPC11 deficiency additionally disrupts autophagic flux and mitochondrial ATP production and network architecture, in a domain-dependent manner [PMID:31575891, PMID:37197784]. Recessive TRAPPC11 mutations cause a congenital disorder of glycosylation presenting with muscular dystrophy and neuropathology [PMID:29855340, PMID:34648194].","teleology":[{"year":2013,"claim":"Established TRAPPC11 as a bona fide TRAPP complex subunit and showed that patient mutations act by disrupting complex assembly and Golgi-exit trafficking, defining the molecular basis of disease.","evidence":"Co-immunoprecipitation of TRAPP components and trafficking/Golgi-morphology assays with two patient mutations in fibroblasts","pmids":["23830518"],"confidence":"High","gaps":["Which TRAPP subunits TRAPPC11 directly contacts not resolved","No structural model of the binding interface","Mechanism linking complex disruption to delayed Golgi exit unknown"]},{"year":2016,"claim":"Revealed a TRAPPC11-specific role in LLO biosynthesis and N-glycosylation distinct from its trafficking function, connecting TRAPP to the glycosylation machinery.","evidence":"Zebrafish mutant LLO quantification, terpenoid-pathway qRT-PCR, pharmacological phenocopy, and selective siRNA depletion of individual TRAPP subunits in human cells","pmids":["26912795"],"confidence":"High","gaps":["Direct biochemical link between TRAPPC11 and LLO synthesis enzymes not established","Mechanism of UPR activation downstream of hypoglycosylation unclear","Cause of lipid droplet accumulation not defined"]},{"year":2016,"claim":"Confirmed in an independent patient that reduced full-length TRAPPC11 produces both impaired Golgi arrival and exit alongside LAMP1 hypoglycosylation, reinforcing the dual trafficking/glycosylation phenotype.","evidence":"Western blot, trafficking marker assays, and LAMP1 glycosylation immunofluorescence in patient fibroblasts with a splice mutation","pmids":["27707803"],"confidence":"Medium","gaps":["Single lab, single patient","No reconstitution of LLO/glycosylation defect","Residual full-length protein levels not quantitatively linked to phenotype severity"]},{"year":2018,"claim":"Connected TRAPPC11 to the dystroglycanopathies by demonstrating α-dystroglycan hypoglycosylation, broadening the disease classification to include a membrane trafficking gene.","evidence":"Immunofluorescence and western blot for α-dystroglycan in muscle biopsy plus live-cell trafficking in patient fibroblasts","pmids":["29855340"],"confidence":"Medium","gaps":["Whether α-dystroglycan defect is direct or secondary to general hypoglycosylation unknown","Single lab","No tissue-specific mechanism for muscle vulnerability"]},{"year":2019,"claim":"Mapped functional contributions to specific TRAPPC11 domains, showing the C-terminus and foie gras domain are required for autophagic flux whereas the Gly980Arg variant spares autophagy, establishing domain-specific roles.","evidence":"Trafficking, glycosylation, and autophagic flux (LC3-II ± bafilomycin) assays across distinct patient variants","pmids":["31575891"],"confidence":"Medium","gaps":["Molecular mechanism linking TRAPPC11 to autophagic flux unknown","Single lab","Structural basis for domain-specific effects not determined"]},{"year":2021,"claim":"Extended the glycosylation defect to brain tissue including Purkinje cells and dentate neurons, framing TRAPPC11-opathy as an N-linked CDG with central nervous system involvement.","evidence":"Trafficking assays and IIH6 α-dystroglycan immunofluorescence in muscle biopsy and post-mortem brain plus western blot","pmids":["34648194"],"confidence":"Medium","gaps":["Neuron-specific mechanism not addressed","Single lab","Causality between trafficking defect and neuropathology not demonstrated"]},{"year":2023,"claim":"Expanded TRAPPC11 function beyond trafficking and glycosylation by linking deficiency to impaired mitochondrial ATP production and altered network architecture.","evidence":"Mitochondrial ATP production assays and network imaging in patient-derived cells","pmids":["37197784"],"confidence":"Low","gaps":["Single lab, single study with limited mechanistic follow-up","Whether mitochondrial defect is direct or secondary unknown","No molecular pathway connecting TRAPPC11 to mitochondria"]},{"year":2024,"claim":"Reaffirmed the CDG classification by showing defective ER-to-Golgi transport with reduced LAMP2 and ICAM-1 glycoprotein expression in a further patient.","evidence":"Membrane trafficking assays and western blot/immunofluorescence for LAMP2 and ICAM-1 in patient fibroblasts","pmids":["38564972"],"confidence":"Low","gaps":["Single patient, single lab","Replicates prior findings without new mechanistic depth","Selectivity of affected glycoproteins not explained"]},{"year":null,"claim":"The biochemical mechanism by which TRAPPC11 uniquely promotes LLO biosynthesis, and how its loss propagates to autophagy and mitochondrial dysfunction, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No direct molecular link between TRAPPC11 and dolichol/LLO synthesis enzymes","No structural model of TRAPPC11 within the TRAPP complex","Causal chain from trafficking defect to mitochondrial and autophagic phenotypes undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,2]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4,5,7]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0,2,5,7]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,3]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[4]}],"complexes":["TRAPP complex"],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q7Z392","full_name":"Trafficking protein particle complex subunit 11","aliases":[],"length_aa":1133,"mass_kda":128.9,"function":"Involved in endoplasmic reticulum to Golgi apparatus trafficking at a very early stage","subcellular_location":"Golgi apparatus; Golgi apparatus, cis-Golgi network","url":"https://www.uniprot.org/uniprotkb/Q7Z392/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/TRAPPC11","classification":"Common Essential","n_dependent_lines":1174,"n_total_lines":1208,"dependency_fraction":0.9718543046357616},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000168538","cell_line_id":"CID000471","localizations":[{"compartment":"golgi","grade":3},{"compartment":"vesicles","grade":3},{"compartment":"cytoplasmic","grade":1}],"interactors":[{"gene":"TRAPPC2B;TRAPPC2","stoichiometry":10.0},{"gene":"TRAPPC13","stoichiometry":10.0},{"gene":"TRAPPC3","stoichiometry":10.0},{"gene":"TRAPPC8","stoichiometry":10.0},{"gene":"TRAPPC6B","stoichiometry":10.0},{"gene":"TRAPPC2","stoichiometry":10.0},{"gene":"ARL6IP6","stoichiometry":0.2},{"gene":"TRAPPC1","stoichiometry":0.2},{"gene":"YWHAB","stoichiometry":0.2},{"gene":"PYGL","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000471","total_profiled":1310},"omim":[{"mim_id":"620166","title":"MUSCULAR DYSTROPHY, CONGENITAL, WITH OR WITHOUT SEIZURES; MYOS","url":"https://www.omim.org/entry/620166"},{"mim_id":"615356","title":"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 18; LGMDR18","url":"https://www.omim.org/entry/615356"},{"mim_id":"614781","title":"TECTONIN BETA-PROPELLER REPEAT-CONTAINING 1; TECPR1","url":"https://www.omim.org/entry/614781"},{"mim_id":"614138","title":"TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 11; TRAPPC11","url":"https://www.omim.org/entry/614138"},{"mim_id":"604027","title":"GOLGI SNAP RECEPTOR COMPLEX MEMBER 2; GOSR2","url":"https://www.omim.org/entry/604027"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Cytosol","reliability":"Uncertain"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRAPPC11"},"hgnc":{"alias_symbol":["FLJ12716","gry","foigr"],"prev_symbol":["C4orf41"]},"alphafold":{"accession":"Q7Z392","domains":[{"cath_id":"3.40.50","chopping":"2-216","consensus_level":"medium","plddt":88.0941,"start":2,"end":216},{"cath_id":"-","chopping":"302-324_339-400_407-467","consensus_level":"medium","plddt":90.0978,"start":302,"end":467},{"cath_id":"-","chopping":"473-574","consensus_level":"high","plddt":90.4261,"start":473,"end":574},{"cath_id":"2.60.40.10","chopping":"581-644_653-749","consensus_level":"high","plddt":84.4404,"start":581,"end":749},{"cath_id":"2.60.40.10","chopping":"755-869","consensus_level":"high","plddt":88.7441,"start":755,"end":869},{"cath_id":"2.60.40.10","chopping":"889-1011","consensus_level":"high","plddt":87.4505,"start":889,"end":1011},{"cath_id":"2.60.40.10","chopping":"1015-1120","consensus_level":"high","plddt":87.8677,"start":1015,"end":1120}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7Z392","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q7Z392-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q7Z392-F1-predicted_aligned_error_v6.png","plddt_mean":87.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRAPPC11","jax_strain_url":"https://www.jax.org/strain/search?query=TRAPPC11"},"sequence":{"accession":"Q7Z392","fasta_url":"https://rest.uniprot.org/uniprotkb/Q7Z392.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q7Z392/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7Z392"}},"corpus_meta":[{"pmid":"11773003","id":"PMC_11773003","title":"Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons?","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11773003","citation_count":242,"is_preprint":false},{"pmid":"23830518","id":"PMC_23830518","title":"Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23830518","citation_count":89,"is_preprint":false},{"pmid":"11134005","id":"PMC_11134005","title":"Identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11134005","citation_count":85,"is_preprint":false},{"pmid":"29855340","id":"PMC_29855340","title":"TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy.","date":"2018","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/29855340","citation_count":48,"is_preprint":false},{"pmid":"26322222","id":"PMC_26322222","title":"Congenital muscular dystrophy with fatty liver and infantile-onset cataract caused by TRAPPC11 mutations: broadening of the phenotype.","date":"2015","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/26322222","citation_count":43,"is_preprint":false},{"pmid":"27707803","id":"PMC_27707803","title":"A novel TRAPPC11 mutation in two Turkish families associated with cerebral atrophy, global retardation, scoliosis, achalasia and alacrima.","date":"2016","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27707803","citation_count":40,"is_preprint":false},{"pmid":"11352648","id":"PMC_11352648","title":"Two-hybrid cloning identifies an RNA-binding protein, GRY-RBP, as a component of apobec-1 editosome.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11352648","citation_count":35,"is_preprint":false},{"pmid":"26912795","id":"PMC_26912795","title":"trappc11 is required for protein glycosylation in zebrafish and humans.","date":"2016","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26912795","citation_count":34,"is_preprint":false},{"pmid":"28827486","id":"PMC_28827486","title":"Siblings With Mutations in TRAPPC11 Presenting With Limb-Girdle Muscular Dystrophy 2S.","date":"2017","source":"Journal of clinical neuromuscular disease","url":"https://pubmed.ncbi.nlm.nih.gov/28827486","citation_count":22,"is_preprint":false},{"pmid":"34648194","id":"PMC_34648194","title":"TRAPPC11-related muscular dystrophy with hypoglycosylation of alpha-dystroglycan in skeletal muscle and brain.","date":"2021","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34648194","citation_count":18,"is_preprint":false},{"pmid":"31575891","id":"PMC_31575891","title":"Characterization of three TRAPPC11 variants suggests a critical role for the extreme carboxy terminus of the protein.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31575891","citation_count":14,"is_preprint":false},{"pmid":"37197784","id":"PMC_37197784","title":"Expanding the phenotypic spectrum of TRAPPC11-related muscular dystrophy: 25 Roma individuals carrying a founder variant.","date":"2023","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37197784","citation_count":9,"is_preprint":false},{"pmid":"30105108","id":"PMC_30105108","title":"Novel TRAPPC11 Mutations in a Chinese Pedigree of Limb Girdle Muscular Dystrophy.","date":"2018","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30105108","citation_count":9,"is_preprint":false},{"pmid":"38564972","id":"PMC_38564972","title":"TRAPPC11-CDG muscular dystrophy: Review of 54 cases including a novel patient.","date":"2024","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38564972","citation_count":8,"is_preprint":false},{"pmid":"33746696","id":"PMC_33746696","title":"Digenic Variants in the TTN and TRAPPC11 Genes Co-segregating With a Limb-Girdle Muscular Dystrophy in a Han Chinese Family.","date":"2021","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33746696","citation_count":8,"is_preprint":false},{"pmid":"39352682","id":"PMC_39352682","title":"Screening and identification of Paenibacillus polymyxa GRY-11 and its biological control potential against apple replant disease.","date":"2024","source":"Folia microbiologica","url":"https://pubmed.ncbi.nlm.nih.gov/39352682","citation_count":7,"is_preprint":false},{"pmid":"33679876","id":"PMC_33679876","title":"Whole-Exome Sequencing and hiPSC Cardiomyocyte Models Identify MYRIP, TRAPPC11, and SLC27A6 of Potential Importance to Left Ventricular Hypertrophy in an African Ancestry Population.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33679876","citation_count":6,"is_preprint":false},{"pmid":"20481626","id":"PMC_20481626","title":"Expression of G-Ry derived from the potato (Solanum tuberosum L.) increases PVY(O) resistance.","date":"2010","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20481626","citation_count":4,"is_preprint":false},{"pmid":"38955476","id":"PMC_38955476","title":"Large TRAPPC11 gene deletions as a cause of muscular dystrophy and their estimated genesis.","date":"2024","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38955476","citation_count":1,"is_preprint":false},{"pmid":"33967689","id":"PMC_33967689","title":"Corrigendum: Digenic Variants in the TTN and TRAPPC11 Genes Co-segregating With a Limb-Girdle Muscular Dystrophy in a Han Chinese Family.","date":"2021","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33967689","citation_count":0,"is_preprint":false},{"pmid":"33173071","id":"PMC_33173071","title":"Publisher Correction: Characterization of three TRAPPC11 variants suggests a critical role for the extreme carboxy terminus of the protein.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33173071","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":11740,"output_tokens":2180,"usd":0.03396,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9276,"output_tokens":3083,"usd":0.061727,"stage2_stop_reason":"end_turn"},"total_usd":0.095687,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"TRAPPC11 is a component of the multiprotein TRAPP complex; disease-causing mutations (p.Gly980Arg and p.Ala372_Ser429del) impair binding of TRAPPC11 to other TRAPP complex components and disrupt Golgi apparatus architecture. The p.Ala372_Ser429del deletion causes normal ER-to-Golgi trafficking but dramatically delayed exit from the Golgi to the cell surface, and results in alterations of lysosomal membrane glycoproteins LAMP1 and LAMP2.\",\n      \"method\": \"Co-immunoprecipitation to assess TRAPP complex binding; marker trafficking experiments in patient fibroblasts; immunofluorescence of Golgi and lysosomal markers\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, trafficking marker experiments, and Golgi morphology analysis with two distinct patient mutations; replicated in subsequent studies\",\n      \"pmids\": [\"23830518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAPPC11 is required for lipid-linked oligosaccharide (LLO) biosynthesis and protein glycosylation; loss of trappc11 in zebrafish reduces LLO levels and triggers compensatory up-regulation of the terpenoid biosynthetic pathway (dolichol production). Depletion of TRAPPC11 (but not other TRAPP components) in human cells causes protein hypoglycosylation, and lipid droplets accumulate in patient fibroblasts. Inhibition of terpenoid or LLO synthesis phenocopies the stressed unfolded protein response (UPR) seen in trappc11 mutants.\",\n      \"method\": \"Zebrafish genetic mutant analysis; LLO quantification; qRT-PCR of terpenoid pathway genes; pharmacological inhibitors phenocopy; siRNA knockdown of individual TRAPP components in human cells; patient fibroblast analysis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (genetic mutant, biochemical LLO assay, pharmacological phenocopy, human cell depletion), conserved across zebrafish and human cells\",\n      \"pmids\": [\"26912795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A TRAPPC11 splice mutation (c.1893+3A>G) causes incomplete exon skipping, reduction in full-length TRAPPC11 protein, hypoglycosylation of LAMP1, and delays in both arrival of cargo at the Golgi and release from the Golgi to the plasma membrane in patient fibroblasts.\",\n      \"method\": \"Western blot; trafficking marker experiments in patient fibroblasts; immunofluorescence for LAMP1 glycosylation\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — trafficking assays and glycosylation readout in patient fibroblasts, single lab, two orthogonal methods\",\n      \"pmids\": [\"27707803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRAPPC11 mutations are associated with hypoglycosylation of α-dystroglycan; compound heterozygous TRAPPC11 mutations in a patient confirm abnormal membrane trafficking in fibroblasts, establishing a link between a membrane trafficking protein and the dystroglycanopathy group of muscular dystrophies.\",\n      \"method\": \"Immunofluorescence and western blotting for α-dystroglycan glycosylation in muscle biopsy; live cell trafficking analysis in patient fibroblasts\",\n      \"journal\": \"Skeletal muscle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunofluorescence, western blot, and live cell trafficking assays in patient material, single lab\",\n      \"pmids\": [\"29855340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The carboxy-terminal region of TRAPPC11 is critical for its functions: a frameshift extending the C-terminus (p.Asp1127Valfs*47) combined with a foie gras domain deletion causes defects in ER-to-Golgi transport, delayed Golgi exit, glycosylation defects of an ER-resident glycoprotein, and autophagic flux defects. Subjects with only the Gly980Arg missense variant showed trafficking and glycosylation defects but not autophagic flux defects, indicating domain-specific functional contributions.\",\n      \"method\": \"Trafficking marker assays in patient fibroblasts; glycosylation assays; autophagic flux assays (LC3-II accumulation with/without bafilomycin)\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple patient variants with orthogonal functional assays (trafficking, glycosylation, autophagy), single lab\",\n      \"pmids\": [\"31575891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAPPC11 is important for TRAPP complex integrity and anterograde membrane transport from the ER to the ER-Golgi intermediate compartment; recessive mutations cause hypoglycosylation of α-dystroglycan in both skeletal muscle and brain (including Purkinje cells and dentate neurons), with neuropathology resembling N-linked congenital disorders of glycosylation.\",\n      \"method\": \"Membrane trafficking assays; immunofluorescence with IIH6 antibody for α-dystroglycan glycosylation in muscle biopsy and post-mortem brain; western blot\",\n      \"journal\": \"Neuropathology and applied neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — trafficking assays and glycosylation immunofluorescence in patient tissue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34648194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRAPPC11 deficiency is associated with decreased mitochondrial ATP production capacity and alterations in mitochondrial network architecture, expanding TRAPPC11's functional role beyond membrane trafficking and glycosylation.\",\n      \"method\": \"Mitochondrial function assays (ATP production) and mitochondrial network imaging in patient-derived cells\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional assays in patient cells but single lab, single study, limited mechanistic follow-up\",\n      \"pmids\": [\"37197784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Membrane trafficking assays in fibroblasts from a TRAPPC11 compound heterozygous patient show defective ER-to-Golgi transport and decreased expression of glycoproteins LAMP2 and ICAM-1, consistent with TRAPPC11-opathy being a congenital disorder of glycosylation (CDG).\",\n      \"method\": \"Membrane trafficking assays; western blot/immunofluorescence for LAMP2 and ICAM-1 in patient fibroblasts\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single patient fibroblast study, single lab, replicates prior findings without new mechanistic depth\",\n      \"pmids\": [\"38564972\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TRAPPC11 is a subunit of the TRAPP III complex that mediates anterograde membrane trafficking from the ER through the Golgi to the cell surface; it is uniquely required (among TRAPP subunits) for lipid-linked oligosaccharide (LLO) biosynthesis and protein N-glycosylation (including glycosylation of α-dystroglycan, LAMP1/2, and ICAM-1), and its loss activates a pathological unfolded protein response, disrupts autophagic flux, and impairs mitochondrial function, with disease-causing mutations in its foie gras or gryzun domains impairing binding to other TRAPP components and disrupting Golgi architecture.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRAPPC11 is a subunit of the multiprotein TRAPP complex that mediates anterograde membrane trafficking, with a particular requirement for cargo exit from the Golgi to the cell surface [#0]. Disease-causing mutations in its C-terminal domains, including the foie gras and gryzun regions, impair TRAPPC11 binding to other TRAPP components and disrupt Golgi architecture, producing a dual defect in ER-to-Golgi transport and delayed Golgi-to-plasma-membrane exit [#0, #4]. Beyond bulk trafficking, TRAPPC11 is uniquely required among TRAPP subunits for lipid-linked oligosaccharide (LLO) biosynthesis and protein N-glycosylation: its loss reduces LLO levels, drives compensatory up-regulation of the terpenoid (dolichol) pathway, and causes protein hypoglycosylation that phenocopies a stressed unfolded protein response [#1]. This glycosylation deficit affects specific substrates including the lysosomal membrane glycoproteins LAMP1/LAMP2, ICAM-1, and α-dystroglycan, the last linking TRAPPC11 loss to the dystroglycanopathy spectrum and to N-linked congenital disorders of glycosylation affecting muscle and brain [#0, #3, #5, #7]. TRAPPC11 deficiency additionally disrupts autophagic flux and mitochondrial ATP production and network architecture, in a domain-dependent manner [#4, #6]. Recessive TRAPPC11 mutations cause a congenital disorder of glycosylation presenting with muscular dystrophy and neuropathology [#3, #5].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established TRAPPC11 as a bona fide TRAPP complex subunit and showed that patient mutations act by disrupting complex assembly and Golgi-exit trafficking, defining the molecular basis of disease.\",\n      \"evidence\": \"Co-immunoprecipitation of TRAPP components and trafficking/Golgi-morphology assays with two patient mutations in fibroblasts\",\n      \"pmids\": [\"23830518\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which TRAPP subunits TRAPPC11 directly contacts not resolved\", \"No structural model of the binding interface\", \"Mechanism linking complex disruption to delayed Golgi exit unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed a TRAPPC11-specific role in LLO biosynthesis and N-glycosylation distinct from its trafficking function, connecting TRAPP to the glycosylation machinery.\",\n      \"evidence\": \"Zebrafish mutant LLO quantification, terpenoid-pathway qRT-PCR, pharmacological phenocopy, and selective siRNA depletion of individual TRAPP subunits in human cells\",\n      \"pmids\": [\"26912795\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link between TRAPPC11 and LLO synthesis enzymes not established\", \"Mechanism of UPR activation downstream of hypoglycosylation unclear\", \"Cause of lipid droplet accumulation not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Confirmed in an independent patient that reduced full-length TRAPPC11 produces both impaired Golgi arrival and exit alongside LAMP1 hypoglycosylation, reinforcing the dual trafficking/glycosylation phenotype.\",\n      \"evidence\": \"Western blot, trafficking marker assays, and LAMP1 glycosylation immunofluorescence in patient fibroblasts with a splice mutation\",\n      \"pmids\": [\"27707803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, single patient\", \"No reconstitution of LLO/glycosylation defect\", \"Residual full-length protein levels not quantitatively linked to phenotype severity\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected TRAPPC11 to the dystroglycanopathies by demonstrating α-dystroglycan hypoglycosylation, broadening the disease classification to include a membrane trafficking gene.\",\n      \"evidence\": \"Immunofluorescence and western blot for α-dystroglycan in muscle biopsy plus live-cell trafficking in patient fibroblasts\",\n      \"pmids\": [\"29855340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether α-dystroglycan defect is direct or secondary to general hypoglycosylation unknown\", \"Single lab\", \"No tissue-specific mechanism for muscle vulnerability\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped functional contributions to specific TRAPPC11 domains, showing the C-terminus and foie gras domain are required for autophagic flux whereas the Gly980Arg variant spares autophagy, establishing domain-specific roles.\",\n      \"evidence\": \"Trafficking, glycosylation, and autophagic flux (LC3-II ± bafilomycin) assays across distinct patient variants\",\n      \"pmids\": [\"31575891\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking TRAPPC11 to autophagic flux unknown\", \"Single lab\", \"Structural basis for domain-specific effects not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended the glycosylation defect to brain tissue including Purkinje cells and dentate neurons, framing TRAPPC11-opathy as an N-linked CDG with central nervous system involvement.\",\n      \"evidence\": \"Trafficking assays and IIH6 α-dystroglycan immunofluorescence in muscle biopsy and post-mortem brain plus western blot\",\n      \"pmids\": [\"34648194\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Neuron-specific mechanism not addressed\", \"Single lab\", \"Causality between trafficking defect and neuropathology not demonstrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Expanded TRAPPC11 function beyond trafficking and glycosylation by linking deficiency to impaired mitochondrial ATP production and altered network architecture.\",\n      \"evidence\": \"Mitochondrial ATP production assays and network imaging in patient-derived cells\",\n      \"pmids\": [\"37197784\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single lab, single study with limited mechanistic follow-up\", \"Whether mitochondrial defect is direct or secondary unknown\", \"No molecular pathway connecting TRAPPC11 to mitochondria\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Reaffirmed the CDG classification by showing defective ER-to-Golgi transport with reduced LAMP2 and ICAM-1 glycoprotein expression in a further patient.\",\n      \"evidence\": \"Membrane trafficking assays and western blot/immunofluorescence for LAMP2 and ICAM-1 in patient fibroblasts\",\n      \"pmids\": [\"38564972\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single patient, single lab\", \"Replicates prior findings without new mechanistic depth\", \"Selectivity of affected glycoproteins not explained\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The biochemical mechanism by which TRAPPC11 uniquely promotes LLO biosynthesis, and how its loss propagates to autophagy and mitochondrial dysfunction, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct molecular link between TRAPPC11 and dolichol/LLO synthesis enzymes\", \"No structural model of TRAPPC11 within the TRAPP complex\", \"Causal chain from trafficking defect to mitochondrial and autophagic phenotypes undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 5, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0, 2, 5, 7]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [\"TRAPP complex\"],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}